Spyre Therapeutics (SYRE) is back on investor radar after management outlined six planned proof of concept readouts for 2026 and reported faster enrollment in its SKYLINE ulcerative colitis trial, alongside appointing experienced commercial leader Kate Tansey Chevlen as CCO.

The share price has reacted quickly to the clinical and leadership updates, with a 1-day share price return of 7.15% and a 90-day share price return of 47.81%. The 1-year total shareholder return of 57.69% shows momentum has been building despite a slightly negative 30-day share price return of 2.44% and a weak 5-year total shareholder return.

If the recent move in Spyre has you looking across the sector, it could be a useful moment to scan other healthcare stocks shaping the next wave of treatments.

After a strong run, Spyre now trades at US$32.80 with analyst targets implying meaningful upside. The real question is whether recent clinical and leadership progress leaves further room for upside or if the market is already pricing in future growth.

Price to Book of 8.5x: Is it justified?

Spyre trades at US$32.80 and the company currently carries a P/B of 8.5x, which sits between cheaper peer averages and a richer biotech industry benchmark.

P/B compares the market value of the company to its net assets on the balance sheet, which can be a useful yardstick for early stage developers that have limited or no revenue and where tangible assets and cash are the main anchors.

According to the checks, Spyre's P/B of 8.5x is described as good value versus a peer average of 14.3x. This suggests investors are paying less per dollar of book value than for similar names, while still paying a premium compared to the broader US Biotechs industry, where the average P/B is 2.7x.

That gap is wide. This means the market is assigning Spyre a richer valuation than the typical biotech, even though it is unprofitable, generates no revenue and is forecast to remain loss making over the next three years, a setup that some investors may see as a trade off between current fundamentals and future clinical potential.

Result: Price-to-book of 8.5x (ABOUT RIGHT)

However, you still need to weigh real risks, including zero current revenue, ongoing losses of US$118.381m, and the possibility that future trial data disappoints.

Build Your Own Spyre Therapeutics Narrative

If you see the data differently or prefer to work through the numbers yourself, you can build your own view in just a few minutes, starting with Do it your way

A great starting point for your Spyre Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use the Simply Wall Street Screener to uncover fresh opportunities.

• Spot potential value plays early by scanning these 880 undervalued stocks based on cash flows that may be pricing in more cash flow strength than the market is currently recognising.
• Ride powerful tech trends by checking out these 26 AI penny stocks that are tying artificial intelligence to real business models and measurable fundamentals.
• Boost your income focus by reviewing these 12 dividend stocks with yields > 3% that combine higher yields with balance sheets you can actually assess in a few quick checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.